Pharmacological Advances in Managing Obesity-Induced Diabetes: Beyond Metformin and Insulin

Nyiramana Mukamurera P.

Faculty of Medicine Kampala International University Uganda

                                                                       ABSTRACT
Type 2 diabetes (T2D) in the context of obesity reflects impaired metabolic flexibility across adipose tissue, liver, muscle, and islets. While metformin and insulin remain foundational, the modern pharmacologic toolkit now targets weight, immunometabolism, organ protection, and endocrine crosstalk. Incretin-based agents (GLP-1 receptor agonists and multi-agonists) deliver substantial weight loss, improve β-cell function, and
reduce cardiovascular (CV) and renal risk. Sodium–glucose cotransporter-2 (SGLT2) inhibitors lower glucose independent of insulin while preventing heart failure events and slowing chronic kidney disease. Thiazolidinediones (TZDs) and selective peroxisome proliferator-activated receptor (PPAR) modulators restore adipose expandability and insulin sensitivity, with trade-offs that invite careful selection. Adjacent therapeutics,
including amylin analogs, combination anti-obesity pharmacotherapy, bile-acid and fibroblast growth factor (FGF21) pathway modulators, and early-stage immunometabolic/mitochondrial agents, offer additional levers to decompress nutrient stress, reduce inflammation, and re-partition substrate. Precision strategies align drug choice with phenotype (hepatic vs peripheral insulin resistance, NAFLD, ASCVD, HF/CKD, appetite drivers),
behavior (meal timing, activity, sleep), and patient goals, often layering medications with nutrition, exercise, and, when indicated, metabolic surgery. Safety requires attention to gastrointestinal effects, genitourinary infections, volume status, bone/edema risk, hypoglycemia from legacy agents, and peri-procedural ketoacidosis with SGLT2 inhibition. This review synthesizes mechanisms and evidence for the major classes beyond metformin/insulin, highlights organ-protective effects, and proposes practical algorithms for combination therapy and deprescribing. We emphasize phenotype-guided, outcome-driven care that uses pharmacology not just to normalize glucose but to modify disease trajectories and lower long-term complication risk.

Keywords: incretin-based therapy; SGLT2 inhibitors; PPAR modulators; anti-obesity pharmacotherapy; precision medicine.

CITE AS: Nyiramana Mukamurera P. (2026). Pharmacological Advances in Managing Obesity Induced Diabetes: Beyond Metformin and Insulin. Research Output Journal of Public Health and Medicine 6(1):30-
35. https://doi.org/10.59298/ROJPHM/2026/613035